Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) said a unit received China's National Medical Products Administration approval to expand the indication of adebrelimab, according to a Thursday Hong Kong bourse filing.
The drug can now be used as neoadjuvant therapy in non-small cell lung cancer. It was previously approved as a first-line treatment of extensive-stage small cell lung cancer.